ChemoMetec A/S (CHEMM) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of ChemoMetec A/S stock DKK 492, price DKK 706, that is 30.3% below the price, quality 83 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range kr 236.80 – kr 1,079 · fair‑value band kr 308.60 – kr 688.70 · the kr 706.00 price screens above the kr 492.12 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow ChemoMetec A/S in your weekly email
Every Wednesday you see whether ChemoMetec A/S is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
Show moreShow less
The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer.
Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer.
In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training.
Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
Stock analysis
ChemoMetec A/S (CHEMM) currently trades at kr 706.00, while our model-based Fair Value estimate is kr 492.12, 30% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 330.03 per share, and 0 of the 26 models we run sit above the kr 706.00 price.
Bear case: the Dividend Discount group reads lowest at kr 85.89, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 308.60 (bear) to kr 688.70 (bull), the price of kr 706.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 83/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
ChemoMetec A/S reported revenue of 511M DKK in FY2026 versus 428M DKK in FY2022, a compound +4.5%/yr. Reported net income was 202M DKK in FY2026, compounding +6.1%/yr from FY2022.
Key figures
Market cap 12.3B DKK (≈ $1.8B) Small · P/E ratio 60.8 · P/S ratio 24.0 · EPS (TTM) kr 11.60 · Dividend yield 1.0% · Net margin 39.5% · Return on equity 28.6% · Return on assets (EBIT) 32.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 92 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 198% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −30%, CHEMM screens richer than that median.
Fair Value models
Bearkr 308.60Fair Value kr 492.12Bullkr 688.70
Price kr 706.00 · Downside -30.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then (kr 1.67 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.97/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2021 (pandemic). Over 10 years: +19.6% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+19.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.0%
Dividend (yield on the price)1.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.0% vs 36.8%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.41% → 49%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+39.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (Denmark: IMF forecast 2.1% a year to 2030, 2.0% from 2016 to 2025) that is about +36.5% a year for the price and +13.2% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score83 · Top 25%
Fair Value upside−30.3% · Below median
Profitability
Return on equity (12 months)28.6% · Top 25%
Return on assets23.4% · Top 25%
Net margin (12 months)39.5% · Top 25%
Operating margin (12 months)49.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)7.4% · Above median
Dividend yield (12 months)1.0% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ChemoMetec A/S Fair Value". https://www.fairvalue-calculator.com/stock/CHEMM
Frequently asked questions
Is ChemoMetec A/S (CHEMM) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of kr 492.12 versus a price of kr 706.00, about 30% lower (overvalued).
What is the fair value of CHEMM?
Our model-based fair value for ChemoMetec A/S is kr 492.12 (as of Nov 8, 2026), built from audited fundamentals. The current price: kr 706.00.
What is the quality score of CHEMM?
ChemoMetec A/S has a Quality Score of 83/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ChemoMetec A/S (CHEMM)?
Our model-based price target is the fair value of kr 492.12 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario kr 308.60, optimistic scenario kr 688.70. It is a calculation from audited fundamentals, not an analyst target.
What is the ChemoMetec A/S stock forecast for 2026?
Our models put fair value at kr 492.12, about 30% lower versus a price of kr 706.00 (overvalued). Cautious scenario kr 308.60, optimistic scenario kr 688.70. The calculation is refreshed regularly with new filings.
What is the revenue of ChemoMetec A/S (CHEMM)?
ChemoMetec A/S reported trailing-twelve-month revenue of about 511M DKK (latest available figure, as of Nov 8, 2026).
Does ChemoMetec A/S pay a dividend?
ChemoMetec A/S currently shows a dividend yield of 0.99% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of ChemoMetec A/S (CHEMM) and when is the ex-dividend date?
ChemoMetec A/S pays a dividend of kr 7.00 per share a year, a dividend yield of 1.0%. The last ex-dividend date was Oct 10, 2025. The payout ratio is 60.1% of earnings. Free cash flow covers the dividend 1.52 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into ChemoMetec A/S (CHEMM)?
For today's price to be fair in a discounted-cash-flow model, ChemoMetec A/S would have to grow free cash flow by +39.3 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of CHEMM use?
Our models discount ChemoMetec A/S at 12.0 %: a base by market capitalisation (small), damped by beta 1.37, country premium for Denmark. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ChemoMetec A/S that is +39.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has ChemoMetec A/S (CHEMM) delivered so far?
Over the past 5 years revenue at ChemoMetec A/S grew +12.7 % a year. The price currently implies free-cash-flow growth of +39.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ChemoMetec A/S (CHEMM) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into ChemoMetec A/S (+39.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ChemoMetec A/S (CHEMM)?
The free-cash-flow yield on the price is 1.48 %: that much free cash flow ChemoMetec A/S produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ChemoMetec A/S (CHEMM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ChemoMetec A/S it is kr 492.12 per share (as of Nov 8, 2026), against a price of kr 706.00. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is ChemoMetec A/S stock overvalued or undervalued in 2026?
As of Nov 8, 2026, CHEMM trades above its calculated fair value: price kr 706.00, fair value kr 492.12, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHEMM?
No. The price is what the market pays today (kr 706.00); the fair value is what the company's own numbers justify (kr 492.12). For ChemoMetec A/S the two are kr 213.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is ChemoMetec A/S worth?
The market values ChemoMetec A/S at about 12.3B DKK (market capitalisation, as of Nov 8, 2026). Per share that is kr 706.00; our models calculate a fair value of kr 492.12 per share.
What do the bullish and bearish scenarios say about CHEMM?
Our models span a range for ChemoMetec A/S: cautious scenario kr 308.60, base kr 492.12, optimistic kr 688.70 per share (as of Nov 8, 2026, price kr 706.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CHEMM?
ChemoMetec A/S trades at a price-to-earnings ratio of 60.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 492.12 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings, FY2026 ex one-offs: 56.7. Other multiples: P/B 16.9, P/S 24.0, EV/EBITDA 45.1.
How solid is the balance sheet of ChemoMetec A/S (CHEMM)?
Balance-sheet figures for ChemoMetec A/S (as of Nov 8, 2026): return on equity 28.6%. They feed the Quality Score of 83/100, which measures business quality independently of the share price.
How far is CHEMM from its 52-week high?
ChemoMetec A/S trades at kr 706.00, about 10% below its 52-week high of kr 782.50 and 198% above the low of kr 236.80 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 492.12 is for.
Which stocks are comparable to ChemoMetec A/S?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ChemoMetec A/S stock attractive at the current price?
The data as of Nov 8, 2026: price kr 706.00, calculated fair value kr 492.12 (−30%), Quality Score 83/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHEMM calculated?
We run ChemoMetec A/S through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 492.12 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. ChemoMetec A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ChemoMetec A/S (CHEMM)?
The closing price on Nov 6, 2026 was kr 706.00. Our model-based fair value is kr 492.12, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ChemoMetec A/S right now?
A high-quality business (quality 83/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (kr 688.70). The favourable scenario is already priced in. A fairly wide model range (kr 308.60 to kr 688.70) leaves room in how you read the outcome.
Where does the earnings growth of ChemoMetec A/S (CHEMM) come from?
Earnings per share at ChemoMetec A/S grew +38.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +20.6 %, EBIT margin +15.0 %, tax rate −1.5 %, residual (interest, one-offs) +1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of ChemoMetec A/S
How large is the market capitalisation of ChemoMetec A/S (CHEMM)?
The market capitalisation of ChemoMetec A/S is 12.3B DKK (≈ $1.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ChemoMetec A/S (CHEMM)?
The price-to-sales ratio of ChemoMetec A/S is 24.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ChemoMetec A/S (CHEMM)?
Earnings per share at ChemoMetec A/S are kr 11.60 (price ÷ EPS = P/E 60.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ChemoMetec A/S (CHEMM)?
The dividend yield of ChemoMetec A/S is 1.0% (payout 60.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ChemoMetec A/S (CHEMM)?
The net margin of ChemoMetec A/S is 39.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ChemoMetec A/S (CHEMM)?
The return on equity (ROE) of ChemoMetec A/S is 28.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ChemoMetec A/S (CHEMM)?
On an EBIT basis the return on assets of ChemoMetec A/S is 32.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ChemoMetec A/S (CHEMM)?
The operating margin of ChemoMetec A/S is 49.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ChemoMetec A/S (CHEMM)?
Revenue at ChemoMetec A/S is growing +7.4% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ChemoMetec A/S (CHEMM)?
Earnings per share at ChemoMetec A/S are growing +51.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does ChemoMetec A/S (CHEMM) hold?
ChemoMetec A/S holds more cash than debt, 286M DKK net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ChemoMetec A/S in the live analysis
One click puts ChemoMetec A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026